Xencor paid its 5 named executives $11.1M in total in FY2025 (Dec). CEO Bassil I. Dahiyat was paid $5.5M of that.
Pay$100 in the stock at the end of FY20 → $35
Pay of each named executive
Bassil I. DahiyatPresident, Chief Executive Officer and Director
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
5 years
John R. Desjarlais, Ph.D.Chief Scientific Officer
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
5 years
Bart Jan CornelissenChief Financial Officer
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | Not disclosed |
2 years
Celia E. EckertGeneral Counsel
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
5 years
Nancy K. Valente, M.D.Former Chief Development Officer
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | |||||||
| FY2023 (Dec) | Not disclosed |
3 years
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 7 peers with pay on file was $6.5M. CEO pay of Xencor for that year is not on file.
- 1Revolution Medicines
- 2Arcus Biosciences
- 3IDEAYA Biosciences
- 4Arvinas
- 5Denali Therapeutics
- 6Kura Oncology
- 7Relay Therapeutics
- 8XencorThis companyNot disclosed
- 9Agenus, Inc.Not disclosed
- 10Alector, Inc.Not disclosed
- 11Allogene Therapeutics, Inc.Not disclosed
- 12Corcept TherapeuticsNot disclosed
- 13Deciphera PharmaceuticalsNot disclosed
- 14IGM Biosciences, Inc.Not disclosed
- 15Inhibrx, Inc.Not disclosed
- 16Iovance BiotherapeuticsNot disclosed
- 17SpringWorks Therapeutics, Inc.Not disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.